lptx - Search News

Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral

H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock rating from Buy to Neutral. The downgrade has intensified pressure on LPTX shares,

ETF Daily News · 5h

Leap Therapeutics (NASDAQ:LPTX) Cut to Hold at Baird R W

Leap Therapeutics (NASDAQ:LPTX – Get Free Report) was downgraded by Baird R W from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports. Several other equities analysts also recently issued reports on the stock.

American Association of Individu… · 3d

Why Leap Therapeutics, Inc.’s (LPTX) Stock Is Down 71.11%

Leap Therapeutics, Inc.’s LPTX share price has dipped by 71.11%, which has investors questioning if this is right time to buy.

Business Insider · 1d

Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data

Fintel on MSN · 1d

HC Wainwright & Co. Downgrades Leap Therapeutics (LPTX)

Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) from Buy to Neutral. Analyst Price Forecast Suggests 1,441.50% Upside As of January 28,

Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining

Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

2don MSN

Leap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancer

Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Leap Therapeutics (LPTX) and Immunovant (IMVT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Leap Therapeutics (LPTX – Research Report) ...

Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

The Pharma Letter1d

Leap halts gastric cancer program, changes course

Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug ...

Leap Therapeutics reports initial data from DeFianCe, DisTinGuish studies

Leap Therapeutics (LPTX) announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab in combination with ...

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results